A Study of LY3200327 in Healthy Participants
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 6/17/2016 |
| Start Date: | November 2015 |
| End Date: | August 2016 |
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3200327 in Healthy Subjects
The purpose of this study is to look at the safety and tolerability of single doses of
LY3200327 when given to healthy male and female participants either by injection under the
skin or by drip into a vein. The study will help determine how the drug behaves inside the
body and how long it takes to disappear from the body. The study will also look for
anti-drug antibodies and how these may affect how LY3200327 acts in your body.
The study is expected to last approximately 12 weeks (with screening evaluations up to 4
weeks prior).
LY3200327 when given to healthy male and female participants either by injection under the
skin or by drip into a vein. The study will help determine how the drug behaves inside the
body and how long it takes to disappear from the body. The study will also look for
anti-drug antibodies and how these may affect how LY3200327 acts in your body.
The study is expected to last approximately 12 weeks (with screening evaluations up to 4
weeks prior).
Inclusion Criteria:
- At the time of initial screening, in general good health
- First-generation healthy Japanese (age 20 to 65 years) will be included
Exclusion Criteria:
- Pregnancy or breastfeeding during the study
- Chronic infection
- Treatment with prohibited medications
We found this trial at
1
site
Glendale, California 91206
Principal Investigator: Hakop Gevorkyan, MD
Phone: 800-239-4367
Click here to add this to my saved trials
